BIOE RX ADR : BioLineRx to Present at the BIO CEO & Investor Conference 2012
02/07/2012 | 07:10am
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development
company, announced today that its Chief Executive Officer, Kinneret
Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip
Serlin, will be presenting at the 2012 BIO CEO & Investor Conference in
New York.
Dr. Savitsky and Mr. Serlin are scheduled to present at 10:00 AM EST on
Tuesday, February 14th. A live Webcast of the presentation will be
available on the BioLineRx Website at http://www.biolinerx.com/default.asp?pageid=63&itemid=107.
A replay will be available one hour after the presentation ends and will
be accessible for three months following the presentation.
About BioLineRx
BioLineRx Ltd. is a publicly-traded biopharmaceutical development
company. It is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx's current portfolio consists of five clinical stage
candidates: BL-1020 for schizophrenia has commenced a Phase II/III
study; BL-1040, for prevention of pathological cardiac remodeling
following a myocardial infarction, is currently undergoing a pivotal
CE-Mark registration trial and has been out-licensed to Ikaria Inc. for
a total deal value of $282.5 million, in addition to sales royalties;
BL-5010 for non-surgical removal of skin lesions has completed a Phase
I/II study; BL-1021 for neuropathic pain is in Phase I development and
BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed
Phase I. In addition, BioLineRx has 13 products in various pre-clinical
development stages for a variety of indications, including central
nervous system diseases, oncology, infectious diseases, cardiovascular
and autoimmune diseases.
BioLineRx's business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government's Office of the Chief Scientist (OCS). The final stage
includes partnering with medium and large pharmaceutical companies for
advanced clinical development (Phase III) and commercialization. For
more information on BioLineRx, please visit www.biolinerx.com.
KCSA Strategic Communications
Garth Russell / Todd Fromer
1
212-896-1250 / 1 212-896-1250
grussell@kcsa.com
/ tfromer@kcsa.com
or
BioLineRx
Ltd.
Tsipi Haitovsky, Public Relations
+972-3-6240871
tsipih@netvision.net.il
© Business Wire 2012
